Rate My Professor Julian Gillmore

Gillmore's clinical research centres on the pathogenesis, diagnosis, treatment, and prognosis of systemic amyloidosis, particularly hereditary transthyretin (ATTR) amyloidosis, AL amyloidosis, and cardiac amyloidosis. He led the first-in-human in vivo CRISPR-Cas9 gene editing trial for transthyretin amyloidosis, published in the New England Journal of Medicine (2021), demonstrating durable reduction in serum transthyretin and halting disease progression. Key publications include 'Nonbiopsy diagnosis of cardiac transthyretin amyloidosis' (2016, over 2,300 citations), 'Systemic amyloidosis' (2016), 'Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group' (2021), and 'Natural history and outcome in systemic AA amyloidosis' (2007). With over 250 peer-reviewed articles cited tens of thousands of times, he has supervised numerous postgraduate MD and PhD students. His contributions include developing a UK haematologist network for AL amyloidosis, leading the first randomised controlled trial for AL amyloidosis with the UK Myeloma Forum, co-founding a patient support group, authoring the British Guidelines on AL Amyloidosis management (2013), and pioneering links between amyloid fibril precursor protein abundance and clinical outcomes in a 2001 Lancet paper. Recent work shows potential for reversing cardiac amyloidosis through novel therapies.